Clinical Evaluation of Skin Microbiome an Over-The-Counter (OTC) Drug for Atopic Dermatitis

Purpose

This is a research study. The over-the-counter (OTC) drug for atopic dermatitis being tested is not approved as a treatment for the participants' atopic dermatitis condition. In participating in this study, the investigators will analyze the participants' skin microbiome, measure skin hydration and barrier function, and assess clinical improvements to help us understand the potential impact of the investigational OTC drug on atopic dermatitis and skin microbiome balance.

Condition

  • Atopic Dermatitis (AD)

Eligibility

Eligible Ages
Between 18 Years and 65 Years
Eligible Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Previously diagnosed Atopic Dermatitis with active, visible flare-ups at time of screening - Present dry/itchy skin patches on forearm, back of the hand, or posterior lower leg suitable for treatment assessment - Evidence of inflammatory disease (documented diagnosis and current active symptoms) - Stable skincare routine for 4 weeks prior to screening - Subject willing to avoid conflicting topical treatments during study period - Subject being used to applying topical treatments for atopic dermatitis General: - Healthy subject apart from atopic dermatitis - Subject having given free informed, written consent - Subject willing to adhere to protocol and study procedures

Exclusion Criteria

  • Pregnant or nursing woman or woman planning to get pregnant during the study - Recent (within 4 weeks) or current history of using atopic dermatitis biological drugs, such as dupilumab, lebrikizumab, nemolizumab, and tralokinumab - Recent use of systemic antibiotics, steroids, or immunomodulators (within 4 weeks) - Active skin infections unrelated to atopic dermatitis - Severe dermatologic conditions requiring immediate medical intervention - Use of topical or systemic treatment during previous weeks liable to interfere with assessment - Subject having undergone surgery under general anaesthesia within the previous month - Excessive exposure to sunlight or UV-rays within the previous month - Subject having scars, tattoos on the forearms that would interfere with assessments - Subject enrolled in another clinical trial during the study period and/or during the past 30 days

Study Design

Phase
Phase 1
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Atopic Dermatitis OTC Product
  • Drug: OTC Drug for Atopic Dermatitis in Cream form
    OTC Cosmetic Cream Formulation
No Intervention
No Product

Recruiting Locations

Sequential Skin
New York, New York 10013
Contact:
Peca
718-902-6228
clinical@sequential.bio

More Details

NCT ID
NCT07146971
Status
Recruiting
Sponsor
Good Molecules, LLC

Study Contact

Peca
718-902-6228
sibora@sequential.bio